Invivyd (NASDAQ:IVVD) is a biotechnology company focused on developing innovative solutions to combat infectious diseases, with a particular emphasis on antibodies designed to prevent and treat various viral infections. Their operations span from early-stage research to advanced clinical trials, aiming to address the unmet medical needs in the infectious disease space. Invivyd's projects include developing therapies that could provide immediate and long-term immunity against challenging viruses, leveraging cutting-edge technology and scientific research. The company's objectives are centered around delivering high-impact solutions to global health threats, fostering partnerships with leading health organizations, and ultimately, improving patient outcomes through the power of immunology and biotechnology innovations.